Annual Current Liabilities
$21.83 M
+$127.00 K+0.59%
31 December 2023
Summary:
Prelude Therapeutics Incorporated annual total current liabilities is currently $21.83 million, with the most recent change of +$127.00 thousand (+0.59%) on 31 December 2023. During the last 3 years, it has risen by +$10.45 million (+91.90%). PRLD annual current liabilities is now at all-time high.PRLD Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Current Liabilities
$22.22 M
-$1.11 M-4.76%
30 September 2024
Summary:
Prelude Therapeutics Incorporated quarterly total current liabilities is currently $22.22 million, with the most recent change of -$1.11 million (-4.76%) on 30 September 2024. Over the past year, it has increased by +$5.33 million (+31.56%). PRLD quarterly current liabilities is now -4.76% below its all-time high of $23.34 million, reached on 30 June 2024.PRLD Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PRLD Current Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +0.6% | +31.6% |
| 3 y3 years | +91.9% | +13.0% |
| 5 y5 years | +792.1% | - |
PRLD Current Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +91.9% | -4.8% | +46.3% |
| 5 y | 5 years | at high | +792.1% | -4.8% | +359.6% |
| alltime | all time | at high | +792.1% | -4.8% | +359.6% |
Prelude Therapeutics Incorporated Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $22.22 M(-4.8%) |
| June 2024 | - | $23.34 M(+32.3%) |
| Mar 2024 | - | $17.64 M(-19.2%) |
| Dec 2023 | $21.83 M(+0.6%) | $21.83 M(+29.2%) |
| Sept 2023 | - | $16.89 M(+11.2%) |
| June 2023 | - | $15.19 M(-22.7%) |
| Mar 2023 | - | $19.66 M(-9.4%) |
| Dec 2022 | $21.70 M | $21.70 M(+0.7%) |
| Sept 2022 | - | $21.56 M(+36.4%) |
| June 2022 | - | $15.81 M(-1.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $16.07 M(-16.3%) |
| Dec 2021 | $19.20 M(+68.8%) | $19.20 M(-2.3%) |
| Sept 2021 | - | $19.66 M(+34.0%) |
| June 2021 | - | $14.68 M(+18.1%) |
| Mar 2021 | - | $12.42 M(+9.2%) |
| Dec 2020 | $11.38 M(+135.3%) | $11.38 M(+0.1%) |
| Sept 2020 | - | $11.36 M(+101.4%) |
| June 2020 | - | $5.64 M(+16.6%) |
| Dec 2019 | $4.83 M(+97.6%) | $4.83 M |
| Dec 2018 | $2.45 M | - |
FAQ
- What is Prelude Therapeutics Incorporated annual total current liabilities?
- What is the all time high annual current liabilities for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated annual current liabilities year-on-year change?
- What is Prelude Therapeutics Incorporated quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated quarterly current liabilities year-on-year change?
What is Prelude Therapeutics Incorporated annual total current liabilities?
The current annual current liabilities of PRLD is $21.83 M
What is the all time high annual current liabilities for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high annual total current liabilities is $21.83 M
What is Prelude Therapeutics Incorporated annual current liabilities year-on-year change?
Over the past year, PRLD annual total current liabilities has changed by +$127.00 K (+0.59%)
What is Prelude Therapeutics Incorporated quarterly total current liabilities?
The current quarterly current liabilities of PRLD is $22.22 M
What is the all time high quarterly current liabilities for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high quarterly total current liabilities is $23.34 M
What is Prelude Therapeutics Incorporated quarterly current liabilities year-on-year change?
Over the past year, PRLD quarterly total current liabilities has changed by +$5.33 M (+31.56%)